Peripheral Neuropathy Phenotyping in Rat Models of Type 2 Diabetes Mellitus: Evaluating Uptake of the Neurodiab Guidelines and Identifying Future Directions

Hossain, MJ; Kendig, MD; Letton, ME; Morris, MJ; Arnold, R

Peripheral Neuropathy Phenotyping in Rat Models of Type 2 Diabetes Mellitus: Evaluating Uptake of the Neurodiab Guidelines and Identifying Future Directions

Hossain, MJ Kendig, MD Letton, ME Morris, MJ Arnold, R

Permalink

Publisher:: Korean Diabetes Association
Publication Type:: Journal Article
Citation:: Diabetes & Metabolism Journal, 2022, 46, (2), pp. 198-221
Issue Date:: 2022-03-31

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (847.22 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Hossain, MJ
dc.contributor.author	Kendig, MD
dc.contributor.author	Letton, ME
dc.contributor.author	Morris, MJ
dc.contributor.author	Arnold, R
dc.date.accessioned	2022-03-29T21:49:04Z
dc.date.available	2022-03-29T21:49:04Z
dc.date.issued	2022-03-31
dc.identifier.citation	Diabetes & Metabolism Journal, 2022, 46, (2), pp. 198-221
dc.identifier.issn	2233-6079
dc.identifier.issn	2233-6087
dc.identifier.uri	http://hdl.handle.net/10453/155679
dc.description.abstract	<jats:p>Diabetic peripheral neuropathy (DPN) affects over half of type 2 diabetes mellitus (T2DM) patients, with an urgent need for effective pharmacotherapies. While many rat and mouse models of T2DM exist, the phenotyping of DPN has been challenging with inconsistencies across laboratories. To better characterize DPN in rodents, a consensus guideline was published in 2014 to accelerate the translation of preclinical findings. Here we review DPN phenotyping in rat models of T2DM against the ‘Neurodiab’ criteria to identify uptake of the guidelines and discuss how DPN phenotypes differ between models and according to diabetes duration and sex. A search of PubMed, Scopus and Web of Science databases identified 125 studies, categorised as either diet and/or chemically induced models or transgenic/spontaneous models of T2DM. The use of diet and chemically induced T2DM models has exceeded that of transgenic models in recent years, and the introduction of the Neurodiab guidelines has not appreciably increased the number of studies assessing all key DPN endpoints. Combined high-fat diet and low dose streptozotocin rat models are the most frequently used and well characterised. Overall, we recommend adherence to Neurodiab guidelines for creating better animal models of DPN to accelerate translation and drug development.</jats:p>
dc.language	en
dc.publisher	Korean Diabetes Association
dc.relation.ispartof	Diabetes & Metabolism Journal
dc.relation.isbasedon	10.4093/dmj.2021.0347
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Peripheral Neuropathy Phenotyping in Rat Models of Type 2 Diabetes Mellitus: Evaluating Uptake of the Neurodiab Guidelines and Identifying Future Directions
dc.type	Journal Article
utslib.citation.volume	46
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
dc.date.updated	2022-03-29T21:49:03Z
pubs.issue	2
pubs.publication-status	Accepted
pubs.volume	46
utslib.citation.issue	2

Abstract:

Diabetic peripheral neuropathy (DPN) affects over half of type 2 diabetes mellitus (T2DM) patients, with an urgent need for effective pharmacotherapies. While many rat and mouse models of T2DM exist, the phenotyping of DPN has been challenging with inconsistencies across laboratories. To better characterize DPN in rodents, a consensus guideline was published in 2014 to accelerate the translation of preclinical findings. Here we review DPN phenotyping in rat models of T2DM against the ‘Neurodiab’ criteria to identify uptake of the guidelines and discuss how DPN phenotypes differ between models and according to diabetes duration and sex. A search of PubMed, Scopus and Web of Science databases identified 125 studies, categorised as either diet and/or chemically induced models or transgenic/spontaneous models of T2DM. The use of diet and chemically induced T2DM models has exceeded that of transgenic models in recent years, and the introduction of the Neurodiab guidelines has not appreciably increased the number of studies assessing all key DPN endpoints. Combined high-fat diet and low dose streptozotocin rat models are the most frequently used and well characterised. Overall, we recommend adherence to Neurodiab guidelines for creating better animal models of DPN to accelerate translation and drug development.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155679